Bayer Pays $400M Upfront to Buy into Loxo Cancer Drugs

Bayer, a life science company with focus in health care and agriculture has paid $400 million and committed to over $1 billion to buy into Loxo Oncology’s tropomyosin receptor kinase (TPK) inhibitor franchise. Loxo’s drug, has had a 75% success rate in its midphase...
Tips from Corporate Strategy Experts

Tips from Corporate Strategy Experts

Tips from Corporate Strategy Experts Negotiating Best Deals In Medical Device Business Development As the medical device industry changes, companies are looking to achieve sustainable growth and business development. Corporate strategy executives are deemed the task...
What Is Healthy?

What Is Healthy?

What Is Healthy? Consumers are increasingly becoming more health conscious than ever before. They are examining nutrition labels and taking the time to learn about what is going in to their bodies. Now is the time for food labeling professionals to clarify any...